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Abstract
Background: Despite the good prognosis in patients with transplant organs, limited evidence is available on how
immunosuppressants affect pregnancy. The aim of this study was to determine whether immunosuppressant use
affects the pregnancy outcome and to identify whether there is any need to change the immunosuppressant
before the patient tries to conceive.
Methods: This retrospective cohort study included women with previous kidney transplantation history who visited
the Department of Obstetrics and Gynecology for either infertility or antenatal care between January 2005 and May
2016. A total of 40 cases (36 women) met the inclusion criteria. Statistical analyses were performed using SAS
version 9.4.
Results: There were no differences in the immunosuppressant regimen between the pregnant and non-pregnant
groups (never-pregnant+miscarriage) (P = 0.73). Individual immunosuppressant use was significantly different in
terms of pregnancy outcome among the never-pregnant, miscarriage, and clinical pregnancy groups (azathioprine,
P = 0.01; deflazacort, P < 0.0001). Only deflazacort use differed significantly between the clinical pregnancy and
non-pregnant groups (P = 0.003). After adjusting for factors that may affect pregnancy outcome, deflazacort use
remained significantly associated with a decreased odds ratio for clinical pregnancy (P = 0.02). Cox regression
analysis also showed that deflazacort use was the only remaining factor that could hinder the success of clinical
pregnancy (P = 0.03).
Conclusions: Our study suggests that the type of immunosuppressive regimen may not affect the success of
clinical pregnancy. However, deflazacort may decrease the possibility of clinical pregnancy in women with kidney
transplant when they try to conceive.
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Introduction
Since the first successful kidney transplantation
performed in 1954 by Dr. Joseph E. Murray, the number
of people who live longer and healthier lives continues
to increase each year. About 126,670 patients underwent
organ transplantation in 2015 worldwide, with the
kidney being the most commonly transplanted organ
(84,347 cases), according to statistics from the Global
Observatory on Donation and Transplantation (www.
transplant-observatory.org). The first successful
pregnancy after kidney transplantation was reported in
1956 [1] and the first pregnancy following in vitro
fertilization-embryo transfer (IVF-ET) in a kidney trans-
plant patient was in 1995 [2]. Extensive discussion has
been conducted regarding the adequate conditions
necessary before trying to conceive, such as stable blood
pressure (BP), a normally functioning transplant organ,
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and infrequent graft rejections [3, 4]. For years, observa-
tions suggested that transplantation and immunosup-
pressant use may not interfere with the fertility of
women [5], but may affect the pregnancy outcome such
as intrauterine growth restriction and preeclampsia,
leading to preterm delivery [6]. Given the effect of
chronic disease and renal dysfunction, which may affect
steroid hormone metabolism, infertility related to anovu-
lation has been suggested as a possible infertility factor;
however, after transplantation, the increase in ovulation
resumption may lead to incidental pregnancy [5]. The
number of patients trying to conceive is increasing,
owing to improved prognosis and well-being after
transplantation.
However, there is a paucity of information on whether
immunosuppressant use affects the achievement of
pregnancy or the pregnancy outcome. When a kidney
transplant patient considers pregnancy, certain immuno-
suppressants, such as mycophenolate mofetil, may be
substituted because of their potential risk for fetal con-
genital orofacial anomalies and miscarriage; however,
even this remains unclear as no distinct pattern of
congenital anomalies has been identified as of yet [7].
The aim of this study was to determine whether
immunosuppressant use affects the pregnancy outcomes
of women with kidney transplants and to identify
whether there is any need to change the immunosup-
pressant before the patient tries to conceive.
Methods
Study population
Women with a history of kidney transplantation who
visited the Department of Obstetrics and Gynecology for
infertility or antenatal care from January 2005 to May
2016 in Severance Hospital, Yonsei University College of
Medicine were included. Women who were pregnant
before transplantation (n = 6), cases lost to follow-up
(n = 2), and those who used certain immunosuppres-
sants, such as sirolimus (n = 2) were excluded (Fig. 1).
Finally, 40 cases (36 women) were included in this
study: 18 cases of 18 infertile women who visited the
infertility clinic (infertile group) and 22 cases of 18 preg-
nant women who visited the antenatal clinic (fertile group)
after achieving successful conception within a year of
trying to conceive. Prednisolone (Pred) was used as a first
line steroid. Deflazacort (DFZ) was chosen instead of Pred
in patients with diabetes, osteoporosis, and Cushing
syndrome caused by prolonged use of corticosteroids.
Primary infertility was diagnosed in those who had
tried to conceive for more than 1 year without contra-
ception, and secondary infertility was diagnosed in those
who had a previous history of pregnancy but failed to
conceive for more than 1 year. The duration of
attempted conception, cause of end-stage renal disease
(ESRD), time since the transplantation, and whether the
patient had graft rejection and hypertension were
assessed through a retrospective chart review. The time
of data collection for each factor, including the type of
immunosuppressant medication, was within the month
of the last menstruation in the clinical pregnancy and
miscarriage groups or at the start of attempting concep-
tion in the never-pregnant group. The never-pregnant
and miscarriage groups were merged into the
non-pregnant group in analyses to compare with the
clinical pregnancy group [8].
Measurements
Patients’ BP was measured using an automated oscillo-
metric measurement while seated with their arm at heart
level. Hypertension was diagnosed if systolic BP ≥140
mmHg, diastolic BP ≥90mmHg, or antihypertensive
medication was currently used. Blood samples were
taken from the antecubital vein after at least 8 h of fast-
ing. Blood tests commonly included blood urea nitrogen
(BUN) and creatinine (Cr). Some patients who visited
the infertility clinic underwent laboratory testing for
hormones, including the follicle-stimulating hormone,
luteinizing hormone, estradiol, and anti-Müllerian hor-
mone. Renal function was assessed by estimated glom-
erular filtration rate (eGFR) [9, 10], using the following
formula: Modification of Diet in Renal Disease (MDRD)
175 × Cr-1.154 × age-0.203 × 0.742.
To confirm the pregnancy, transvaginal ultrasonog-
raphy was performed by experienced gynecologists using
the available ultrasound systems (Accuvix V20 Prestige,
Medison Co., Seoul, Korea; iU22, Philips Healthcare,
WA, USA; and Voluson E8, GE Medical Systems, Zipf,
Austria). Clinical pregnancy was defined as the presence
of an intrauterine gestational sac with a pulsating fetal
heartbeat detected by ultrasonography. Miscarriage was
defined as confirmed intrauterine gestational sac without
fetal heartbeat on ultrasonography.
All women with infertility underwent testing for tubal
patency by hysterosalpingography and evaluation of pel-
vic anatomy by ultrasonography. Semen parameters were
interpreted using the World Health Organization (2010)
criteria [11]. The causes of infertility were unexplained
infertility, male factor, tubal factor, decreased ovarian
reserve, and endometriosis. The patients who visited the
infertility clinic decided to proceed with intrauterine
insemination (IUI; n = 5) or IVF-ET (n = 11) based on
the cause of their infertility. Women with unexplained
infertility in conjunction to irregular menstruation tried
to conceive naturally using ovulation induction (n = 2).
Statistical analysis
Data was analyzed using the SAS version 9.4 (SAS Insti-
tute, Cary, NC, USA). The Student t-test and one-way
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analysis of variance were used to compare the means for
normally distributed continuous variables. The
Mann-Whitney U-test and Kruskal-Wallis test were used
to analyze non-parametrically distributed variables. The
Fisher exact and chi-square tests were used to assess cat-
egorical variables. Univariate and multivariate logistic re-
gression analyses were also performed. The logistic
model included the factors that showed significance on
the univariate analysis. Given the uneven distribution of
the adjusting factors, the Firth-type bias-reduced logistic
regression was used for adjustment. Multicollinearity,
goodness of fit, and the predictive power of the logistic
model were checked. Based on the logistic model, Cox’s
regression analyses for clinical pregnancy and trial
period of pregnancy were performed. A P-value < 0.05
was considered statistically significant.
Results
A total of 40 cases in 36 kidney transplant women were
included in this study: 10 cases who had never been
pregnant, 9 cases with miscarriage, and 21 cases with
clinical pregnancy. One patient in the fertile group had
three miscarriages. Two other patients in the fertile
group each had one delivery and one miscarriage.
Among the infertile women, 12 and 6 women had
primary and secondary infertility, respectively. Of these
women, 11 had an unexplained cause for infertility, 2
had infertility due to male factor, 4 had decreased
ovarian reserve, and 1 had severe endometriosis (retain-
ing duplicate causes). In the infertile group, 2, 4, and 12
women attempted pregnancy through natural concep-
tion, IUI, and IVF-ET, respectively. All women in the
fertile group conceived naturally. Twenty-one cases of
clinical pregnancy were achieved through natural con-
ception in 15 women, IUI in 2 women, and IVF-ET in 2
women. The mean age of all participants was 33.8 ± 3.4
years. Mean duration of attempted conception was
17.6 ± 18.2 months and average time interval from the
time of kidney transplant to the time they tried con-
ceiving was 5.9 ± 4.1 years.
Table 1 shows the patients’ baseline characteristics
categorized by pregnancy outcome. The median age
and BP were the lowest in the clinical pregnancy
group, without a significant difference. Serum BUN
level (17.2 mg/dL, P = 0.04) was low and eGFR (60.72,
P = 0.02) was significantly high in the clinical
pregnancy group compared to other groups. The
proportion of patients with diabetes mellitus was sig-
nificantly different among the groups, with two cases
occuring in the never-pregnant group (P = 0.008). The
graft rejection rate was significantly different among
the three groups; the incidence of rejection was high-
est in the miscarriage group and lowest in the clinical
pregnancy group (never-pregnant 30%, miscarriage
66.7%, clinical pregnancy 9.5%, P = 0.01). The cause of
ESRD was predominantly nephrotic syndrome in the
Fig. 1 Flow chart of participant inclusion in the study
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clinical pregnancy group (glomerulonephritis 42.9%, im-
munoglobulin A nephropathy 33.3%) and never-pregnant
group (glomerulonephritis 40%, immunoglobulin A ne-
phropathy 20%), while systemic lupus erythematous (SLE)
(33.3%) was highest in the miscarriage group, but without
significant difference among the groups (P = 0.13).
Immunosuppressant use was analyzed in terms of the
regimen and type of medication. The immunosuppres-
sants analyzed were as follows: cyclosporine (CyA),
tacrolimus (TAC), DFZ, Pred, azathioprine (AZT), and
Table 1 Baseline characteristics of participants according to the pregnancy outcome
Never-pregnant (n = 10) Miscarriage (n = 9) Clinical pregnancy(n = 21) P value
Age (years) 34.5 (29–42) 36 (30–39) 33 (27–41) 0.44
Duration tried to concieve (months) 44 (16–108) 48 (6–96) 22 (6–96) 0.1
Years since transplantation (years) 4 (2–8)a 7 (2–18)a 5.5 (1–14) 0.08
SBP (mmHg) 123 (113–144) 135 (100–162) 120 (100–145) 0.44
DBP (mmHg) 80 (70–92) 76 (60–96) 72 (58–96) 0.2
Serum BUN (mg/dL) 18.85 (8.4–34.4) 25.4 (18.7–37.2)b 17.2 (10.2–35.3)b 0.04
eGFR 55.08 (22–96.6) 39 (9.0–76)b 60.72 (37–89.7)b 0.02
Hypertension 0.59
No 4 (40%) 2 (22.2%) 5 (23.8%)
Yes 6 (60%) 7 (77.8%) 16 (76.2%)
Diabetes melitus 0.04
No 8 (80%) 9 (100%) 21 (100%)
Yes 2 (20%) 0 0
Graft rejection 0.01
No 7 (70%) 3 (33.32%) 19 (90.5%)
Yes 3 (30%) 6 (66.7%)b 2 (9.5%)b
Cause of ESRD 0.13
Unknown 1 (10%) 2 (22.2%) 5 (25%)
SLE 1 (10%) 3 (33.3%) 0
Glomerulonephritis 4 (40%) 2 (22.2%) 9 (42.9%)
Ig A nephropathy 2 (20%) 1 (11.1%) 7 (33.3%)
Congenital anomaly 1 (10%) 1 (11.1%) 0
Diabetes melitus 1 (10%) 0 0
Immunosuppressant regimen 0.3
CI 1 (10%) 2 (22.2%) 6 (28.6%)
CI + ST + AP 6 (60%) 1 (11.1%) 5 (23.8%)
CI + ST 3 (30%) 5 (55.6%) 9 (42.9%)
CI + AP 0 1 (11.1%) 1 (4.8%)
Immunosuppressant use
CyA 3 (30%) 2 (22.2%) 9 (45%) 0.52
TAC 6 (60%) 7 (77.8%) 12 (57.1%) 0.55
DFZ 9 (90%) 1 (11.1%) 2 (9.5%) < 0.0001
Pred 2 (20%) 6 (66.7%) 13 (61.9%) 0.06
Aza 5 (50%) 0 2 (9.5%) 0.01
MMF 2 (20%) 2 (22.2%) 4 (19%) 0.98
Data are presented as the median (minimum to maximum). The P-values were obtained using the analysis of variance and the Kruskal-Wallis test for continuous
variables, and the chi-square test was used for analyzing categorical variables. Post hoc analysis using the Tukey method was performed, which showed a
significant difference between the non-pregnant group and the miscarriage groupa, and the miscarriage group and clinical pregnancy groupb
Note: Duration, period of attempted conception; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular
filtration rate; ESRD, end stage renal disease; SLE, systemic lupus erythematous; Ig, immunoglobulin; CI, calcineurin inhibitor; ST, steroid; AP; antiproliferative drug;
CyA, cyclosporine; TAC, tacrolimus; DFZ, deflazacort; Pred, predinosolone; Aza, azathioprine; MMF, mycophenolate mofetil
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mycophenolate mofetil (MMF). The regimens were
grouped as follows: CI + ST +AP, CI + ST, and CI + AP
(CI, calcineurin inhibitor: CyA and TAC; ST, steroid: DFZ
and Pred; AP, antiproliferative drug: AZT and MMF).
Among the never-pregnant, miscarriage, and clinical
pregnancy groups, the use of AZT (P = 0.01) and DFZ
(P < 0.0001) was significantly different; however, there
was no difference in the immunosuppressive regimen.
None of the patients consumed DFZ on account of
planning for pregnancy. All patients started DFZ dir-
ectly following kidney transplantation as a substitute
for Pred according to medical indications. There were
only two patients with diabetes among the 36 women
in our study.
Table 2 presents a comparison of immunosuppressant
use among never-pregnant, miscarriage, and clinical
pregnancy groups. The clinical pregnancy group had no
significant difference in the regimen used. Regarding
each medication separately, DFZ use was significantly
different between the non-pregnant and clinical preg-
nancy groups (52.6% vs. 9.5%, P = 0.003). Use of other
immunosuppressants was similar between these two
groups. We tried to determine whether there would be
any difference if we grouped the patients according to
the presence of a gestational sac on the ultrasonogram
to either the implantation or the non-implantation
group for failed pregnancies (data not shown). Steroid
use remained significantly different between the two
groups: DFZ use in non-implantation vs. implantation
groups (88.9% vs. 12.9%, P < 0.0001); and Pred use in
non-implantation vs. implantation groups (22.2% vs.
61.3%, P = 0.04). Additionally, AZT use was signifi-
cantly different between the non-implantation and
implantation groups (55.6% vs. 6.5%, P = 0.001). The
immunosuppressive regimen was not different be-
tween the implantation and non-implantation groups.
There were no significant differences in the method
of conception between the non-pregnant and clinical
pregnancy groups according to the immunosuppres-
sant used, except for DFZ (P = 0.02, Table 3) and
MMF (P = 0.02, Table 3).
Lastly, multivariate logistic models, using the
Firth-type bias-reduced method, were utilized for some
factors. The univariate analyses showed that the use of
DFZ and whether the patient experienced graft rejection
at the point of data collection were significantly different
between the clinical pregnancy and non-pregnant groups
(Table 4). After adjusting confounding factors, DFZ was
the only significant immunosuppressant showing de-
creased odds to clinical pregnancy (odds ratio (OR) 0.06,
95% confidence interval (CI) 0.01–0.68, P = 0.02, Table 5).
To examine the hazard factors for clinical pregnancy,
Cox regression models were used (Table 6). Before ad-
justment, whether the patient experienced graft rejection
or not at the point of data collection was a significant
hazardous factor of clinical pregnancy. On the multivari-
ate Cox model, DFZ use was the only significant hazard-
ous factor for clinical pregnancy (hazard ratio (HR) 0.17,
95% CI 0.03–0.86, P = 0.03, Table 6). When the total
duration and cumulative dosage of DFZ used were
included in the respective models, the longer duration
hindered clinical pregnancy (HR 0.97, 95% CI 0.95–0.99,
P = 0.04, Table 6). For the cases that used DFZ, the total
duration of DFZ use was 57 months (median; 25–188
months, min-max) and its cumulative dose was 12,051
mg (median; 672–68,940 mg, min-max).
Table 2 Differences in immunosuppressant use and the
pregnancy outcome
Non-pregnant
(n = 19)
Clinical
pregnancy
(n = 21)
P value
0.73
Regimen CI 3 (15.8%) 6 (28.6%)
CI + ST + AP 7 (36.8%) 5 (23.8%)
CI + ST 8 (42.1%) 9 (42.9%)
CI + AP 1 (5.3%) 1 (4.8%)
Immunosuppressant use CyA 5 (26.3%) 9 (42.9%) 0.27
TAC 13 (68.4%) 12 (57.1%) 0.46
DFZ 10 (52.6%) 2 (9.5%) 0.003
Pred 8 (42.1%) 13 (61.9%) 0.21
Aza 5 (26.3%) 2 (9.5%) 0.16
MMF 4 (21.1%) 4 (19%) 0.87
Note: CI calcineurin inhibitor, ST steroid, AP antiproliferative drug,
CyA cyclosporine, TAC tacrolimus, DFZ deflazacort, Pred predinosolone,
Aza azathioprine, MMF mycophenolate mofetil
Table 3 Differences in immunosuppressant use and the
method of conception
ART
(n = 6)
Natural
conception
(n = 15)
P value
0.08
Regimen CI 1 (16.7%) 5 (33.3%)
CI + ST + AP 3 (50%) 2 (13.3%)
CI + ST 1 (16.7%) 8 (53.3%)
CI + AP 1 (16.7%) 0
Immunosuppressant use CyA 1 (16.7%) 8 (53.3%) 0.13
TAC 5 (83.3%) 7 (46.7%) 0.13
DFZ 2 (33.3%) 0 0.02
Pred 3 (23.1%) 10 (66.7%) 0.48
Aza 1 (16.7%) 1 (16.7%) 0.48
MMF 3 (50%) 1 (6.7%) 0.02
Note: ART assisted reproductive techniques, CI calcineurin inhibitor, ST steroid,
AP antiproliferative drug, CyA cyclosporine, TAC tacrolimus, DFZ deflazacort,
Pred predinosolone, Aza azathioprine, MMF mycophenolate mofetil
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Discussion
Considering the lack of knowledge in how immunosup-
pressants affect successful pregnancy, our study suggests
a possible detrimental effect of DFZ for the first time.
Until now, most studies on the adverse effects of immu-
nosuppressants have focused on the development of
diabetes or osteoporosis with their long-term use. Some
studies have shown their impact on pregnancy complica-
tions and fetal outcome; but studies studying their
impact on either fertility or pregnancy success are few.
Our study suggests that the type of immunosuppressant
regimen may not affect the success of clinical pregnancy;
however, a certain medication-DFZ- may.
In our study, of the 40 cases, 17 cases were on CI and
ST regimen (17/40, 42.5%), 12 on CI with ST and AP
regimen (12/40, 30%), 9 on CI regimen only (9/40,
22.5%), and 2 on CI and AP regimens (2/40, 5%). Little
is known on the effect of immunosuppressants on fertil-
ity. AZT was reported to show teratotoxicity in animal
studies, but not in humans [12]. MMF is a reversible in-
hibitor of inosine monophosphate dehydrogenase, which
blocks de novo purine synthesis and is thereby suggested
as a category D drug in pregnancy. An increased risk of
miscarriage and congenital orofacial malformations,
especially microtia, is reported with MMF use [7]. CI
acts by blocking cytokine secretion necessary for T-cell
activation and proliferation. CyA and TAC are category
C drugs in pregnancy that require strictly monitored
serum levels. There has been no evidence of congenital
anomaly development with these drugs; however, alter-
ation of the immune response in neonates exposed to
TAC in utero is possible [13]. Corticosteroids are mostly
category B drugs in pregnancy that are associated with
multiple maternal adverse effects [14]. Although the
effect of Pred use is still unclear, it has been suggested
that it enhances implantation rate in infertile women
and decreases the risk of miscarriage in women with
idiopathic recurrent pregnancy loss [15, 16]. The effect
of Pred on uterine natural killer (NK) cells may be the
key factor to its positive effect. Pred may inhibit uterine
NK cells in the endometrium [16] and bind to the gluco-
corticoid receptor in the endometrium, which leads to
an immunomodulating effect [17].
DFZ is a heterocyclic corticosteroid, which is an oxa-
zoline derivative of Pred. It was developed in the early
1980s [18] to treat patients with Duchenne muscular
dystrophy [19] and is characterized by high efficacy and
good tolerability because of its substantial lack of fluid
retention and low interference with carbohydrate and
phosphocalcium metabolisms [20]. Given DFZ’s excel-
lent anti-inflammatory properties and good tolerability,
it is preferred in patients with osteoporosis [21] or
diabetes [22]. In our study, there were 2 patients with
diabetes among those 12 patients who used DFZ.
Table 4 Unadjusted odds ratios of factors in clinical pregnancy
Factors Unadjusted OR (95% CI) P value
Age (years) 0.87 (0.72–1.06) 0.17
Duration tried to conceive (months) 0.98 (0.96–1.0) 0.09
Years since transplantation (years) 0.94 (0.80–1.10) 0.45
Hypertension 1.48 (0.37–5.96) 0.58
Serum BUN (mg/dL) 0.94 (0.87–1.03) 0.19
eGFR 1.03 (0.99–1.07) 0.09
Graft rejection 0.12 (0.02–0.65) 0.01
Diabetes mellitus 0.16 (0.004–7.09) 0.35
Cause of ESRD
Unknown 1
SLE 0.07 (0.002–2.49) 0.15
Glomerulonephritis 0.93 (0.16–5.38) 0.94
Ig A nephropathy 1.36 (0.2–9.56) 0.75
Congenital anomaly 0.13 (0.002–6.82) 0.31
Diabetes melitus 0.16 (0.001–25.91) 0.48
Use of ART 0.36 (0.1–1.33) 0.13
CyA 2.1 (0.55–8.0) 0.28
TAC 0.62 (0.17–2.25) 0.46
DFZ 0.09 (0.02–0.53) 0.007
Pred 2.23 (0.63–7.93) 0.21
Aza 0.29 (0.05–1.75) 0.18
MMF 0.88 (0.19–4.16) 0.88
Note: ART assisted reproductive techniques, SBP systolic blood pressure,
DBP diastolic blood pressure, BUN blood urea nitrogen, eGFR estimated
glomerular filtration rate, ESRD end stage renal disease, SLE systemic lupus
erythematous, Ig immunoglobulin, CyA cyclosporine, TAC tacrolimus,
DFZ deflazacort, Pred predinosolone, Aza azathioprine, MMF mycophenolate
mofetil, OR odds ratio, CI confidence interval
Table 5 Adjusted odds ratios of immunosuppressants in clinical
pregnancy
Immunosuppressant Unadjusted OR
(95% CI)
P value Adjusted OR
(95% CI)
P value
CyA 2.1 (0.55–8.0) 0.28 1.38 (0.22–8.89) 0.73
TAC 0.62 (0.17–2.25) 0.46 0.84 (0.16–4.49) 0.84
DFZ 0.09 (0.02–0.53) 0.007 0.06 (0.01–0.68) 0.02
Pred 2.23 (0.63–7.93) 0.21 2.8 (0.53–14.85) 0.23
Aza 0.29 (0.05–1.75) 0.18 0.48 (0.06–4.1) 0.5
MMF 0.88 (0.19–4.16) 0.88 0.78 (0.14–4.39) 0.78
The P-values were obtained using simple and multiple logistic regression
analysis. The analysis was adjusted for age, estimated glomerular filtration rate,
graft rejection after transplantation, diabetes mellitus, and use of assisted
reproductive techniques. The logistic regression analysis was performed for
each immunosuppressant, respectively
Note: CyA, cyclosporine; TAC, tacrolimus; DFZ, deflazacort; Pred, predinosolone;
Aza, azathioprine; MMF, mycophenolate mofetil; OR, odds ratio; CI,
confidence interval
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Although the number of patients using immunosuppres-
sants is consistently increasing, little is known of their
long-term effects during pregnancy. This may be
because the indication for DFZ use was initially for
patients with Duchenne muscular dystrophy who are
less likely to attempt conception because of their under-
lying disease. As DFZ use is increasing in various fields
of autoimmune diseases [23, 24], comparison to Pred
has been done in terms of osteoporosis, cushinoid
features, and body weight [25]. Our study is the first and
only study, to our knowledge, showing adverse effects
regarding fertility in those who use DFZ.
Since the purpose of the study was to identify whether
there is any need to change the immunosuppressant
before trying to conceive, we generated logistic and Cox
hazard models that focused on each immunosuppres-
sant. To minimize the interaction among drugs and to
focus on the effect of each immunosuppressant, multi-
variate models were constructed to include each im-
munosuppressant separately with the factors that
showed significance on univariate analyses. DFZ showed
significantly decreased odds for clinical pregnancy (OR
0.06, P = 0.02) and decreased possibility for achieving
clinical pregnancy (HR 0.17, P = 0.03) after adjustment
on multivariate models. Considering studies which
suggest the positive effects of steroids on pregnancy, our
result showing the possible detrimental effect of DFZ is
unexpected. However, the possible harm of DFZ on con-
ception may be explained by the difference between Pred
and DFZ in inhibiting type 1 11ß-hydroxysteroid
dehydrogenase (type 1 11ß-HSD) [26]. Type 1 11ß-HSD
is an enzyme widely distributed throughout the central
nervous system and peripheral tissues, and it is essential
in hepatic and adipose tissue carbohydrate metabolism
[27]. Decreased type 1 11ß-HSD expression was signifi-
cantly associated with increased uterine NK cell density
especially in the human endometrium [28]. Moreover,
type 1 11ß-HSD has been identified as a key factor in
decidualization of endometrial stromal cells [29]. The
difference in the inhibiting ability of type 1 11ß-HSD
may lead to a different expression of uterine NK cells
and may affect the process of decidualization in the
endometrium, resulting in a detrimental effect in
implantation and successful pregnancy.
In the current study, renal function was better in the
clinical pregnancy group than in the miscarriage group,
exhibiting a significantly high eGFR and low serum BUN
level (Table 1). However, the factors which may reflect
graft function, such as eGFR and graft rejection, were
not the ones with affected odds or hazard after adjust-
ment for clinical pregnancy. Better kidney function with
fewer graft rejection should be associated with better
pregnancy prognosis, resulting in a lower possibility of
miscarriage; however, our study did not prove this
hypothesis. After discovering the possible detrimental
effect of DFZ on clinical pregnancy, we additionally
analyzed whether the duration or cumulative dosage of
DFZ may further affect the clinical pregnancy. The total
duration of DFZ use showed a possible hazardous
impact (Table 6); however, the hazard was not found to
be significant, probably because of the small number of
cases included in this study. There were no cases of
newly developed acute rejection during the period of
trying to conceive.
Our study was subject to several limitations. First, our
study had a small number of patients and was of retro-
spective design. There may be a selective bias as kidney
transplant patients who failed to conceive, but did not
seek fertility treatment might be missed. However, as
kidney transplant patients are usually very concerned
about how their fertility is effected by their medication
use, we believe that most would discuss infertility at
length with their primary physician and seek further
help if needed. Nonetheless, it may be unclear as to
whether infertility in these patients is due to the im-
munosuppressant use or the fact that they did not seek
fertility treatment. Secondly, as DFZ use was limited to
certain diseases and countries, long-term reference data
Table 6 Adjusted hazard ratios of immunosuppressants for clinical pregnancy and duration
Immunosuppressant Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
CyA 0.89 (0.37–2.14) 0.8 0.33 (0.1–1.09) 0.07
TAC 1.16 (0.49–2.79) 0.73 2.99 (0.92–9.72) 0.07
DFZ 0.23 (0.05–0.99) 0.05 0.17 (0.03–0.86) 0.03
Pred 1.28 (0.53–3.11) 0.59 1.06 (0.42–2.72) 0.9
Aza 0.31 (0.07–1.34) 0.12 0.36 (0.08–1.77) 0.21
MMF 0.57 (0.19–1.72) 0.32 0.61 (0.2–1.83) 0.38
Cumulative dose of DFZ (mg) 1.0 0.11 1.0 0.14
Total duration of DFZ use (months) 0.98 (0.95–1.0) 0.06 0.97 (0.95–1.0) 0.04
The P-values were obtained using univariate and multivariate cox regression analyses. The analysis was adjusted for age, eGFR, graft rejection after transplantation,
diabetes mellitus, and use of assisted reproductive techniques. The cox regression multivariate analysis was performed for each immunosuppressant, respectively
Note: CyA cyclosporine, TAC tacrolimus, DFZ deflazacort, Pred predinosolone, Aza azathioprine, MMF mycophenolate mofetil, HR hazard ratio, CI confidence interval
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was unavailable. Finally, it is unclear as to how the im-
munosuppressants may interact with each other and
whether they will negatively impact fertility. On the
other hand, the strength of our study is that, for the first
time, we showed a possible detrimental effect of DFZ in
terms of implantation and success of pregnancy. To our
knowledge, excluding the report demonstrating TAC as
a basic immunosuppressive agent that achieved a high
rate of successful pregnancy [30], this is the only study
that investigated the effect of immunosuppressant use in
fertility and pregnancy outcome.
Conclusions
In conclusion, DFZ may decrease the possibility of clin-
ical pregnancy. The use and effect of immunosuppres-
sants need to be evaluated more thoroughly in future
studies. Before attempting pregnancy, modulating the
immunosuppressant regimen may be required.
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